
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a leader in the diabetes technology industry with a global presence and strong revenue growth potential. Their focus on innovation, worldwide reach, and differentiated technology is expected to continue driving profitability, while their track record of positive clinical outcomes and strong patent portfolio provide a competitive advantage. Their expansion into new markets and commitment to developing new products, along with a highly-rated stock and experienced leadership, make them a solid investment choice.
Bears say
Minimed Group is well-positioned to capitalize on a significant total addressable market for diabetes management solutions, but with only a ~7% penetration rate, there is significant room for competition to enter and potentially erode MiniMed's market share. Additionally, the company's reliance on intensive insulin therapy means it may face challenges as lifestyle management and alternative treatments become more popular. While MiniMed has a strong, unlevered balance sheet, their margins are projected to decline in the near term due to product launches and clinical trials, which could impact profits and cash flow.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares